North–South Summit 2026 | Professor Jia Wang: In the Era of Neoadjuvant Immunotherapy for Triple-Negative Breast Cancer—Is Platinum Still Essential?

North–South Summit 2026 | Professor Jia Wang: In the Era of Neoadjuvant Immunotherapy for Triple-Negative Breast Cancer—Is Platinum Still Essential?

In the era of neoadjuvant immunotherapy for triple-negative breast cancer (TNBC), an important clinical question has emerged: is platinum still indispensable? During the “Deep Dive” session at the 8th North–South Breast Cancer Forum, Professor Jia Wang from Zhongshan Hospital, Dalian University presented an in-depth analysis of this issue. Drawing on treatment goals, mechanistic rationale, clinical evidence, and individualized strategies, she systematically reviewed the role and challenges of platinum agents in neoadjuvant immunotherapy for TNBC and proposed future directions toward precision “de-escalation” therapy.
Breaking News: Academician Binghe Xu Leads PHILA Study Published in The BMJ—A “China Solution” for First-Line Dual Targeting in HER2-Positive Metastatic Breast Cancer

Breaking News: Academician Binghe Xu Leads PHILA Study Published in The BMJ—A “China Solution” for First-Line Dual Targeting in HER2-Positive Metastatic Breast Cancer

On March 16, 2026, the long-term follow-up results of the randomized, double-blind, multicenter Phase III PHILA study were published online in The BMJ. The corresponding author is Academician Binghe Xu from the Cancer Hospital, Chinese Academy of Medical Sciences, with Professor Fei Ma (Cancer Hospital, Chinese Academy of Medical Sciences) and Professor Min Yan (Henan Cancer Hospital) as co–first authors. With a median follow-up of 45.5 months, the study demonstrated that first-line treatment with pyrotinib in combination with trastuzumab and docetaxel significantly improved overall survival (OS) in patients with HER2-positive metastatic breast cancer, reducing the risk of death by 26%. These findings establish a dual-targeted regimen that reflects a distinct “China-developed strategy” for first-line treatment in this population.
North–South Summit 2026 | Professor Hao Wang: When Is the Optimal Timing for Precision Endocrine Testing in HR+/HER2– Metastatic Breast Cancer?

North–South Summit 2026 | Professor Hao Wang: When Is the Optimal Timing for Precision Endocrine Testing in HR+/HER2– Metastatic Breast Cancer?

Precision testing is only as valuable as its timing. During the “Deep Dive” session at the 8th North–South Breast Cancer Forum, Professor Hao Wang from Sichuan Cancer Hospital delivered a focused presentation on the optimal timing of endocrine-related molecular testing in patients with HR+/HER2– metastatic breast cancer.
Annals of Oncology: Academician Binghe Xu and Professor Tao Sun Report the OPTIMAL Study—Oral Paclitaxel Demonstrates Non-Inferiority to Intravenous Therapy in HER2-Negative Advanced Breast Cancer

Annals of Oncology: Academician Binghe Xu and Professor Tao Sun Report the OPTIMAL Study—Oral Paclitaxel Demonstrates Non-Inferiority to Intravenous Therapy in HER2-Negative Advanced Breast Cancer

On March 14, 2026, the international oncology journal Annals of Oncology (2025 IF: 65.4), the official journal of the European Society for Medical Oncology (ESMO), published the results of the international multicenter phase III OPTIMAL trial (NCT03315364). The study was led by Academician Binghe Xu (first author) from the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, and Professor S-B. Kim (corresponding author), with key contributions from Professor Tao Sun (Liaoning Cancer Hospital) and Professor H. Jeong (Asan Medical Center, University of Ulsan College of Medicine), among other international collaborators. For the first time, the study demonstrated that oral paclitaxel (DHP107) is non-inferior to weekly intravenous paclitaxel in first-line treatment of HER2-negative recurrent or metastatic breast cancer, with lower neurotoxicity and greater convenience—offering patients a safer and more accessible therapeutic option.
At the Crest of Innovation | Professors Jian Zhang and Songqing Ye Discuss the Frontiers of ADC Therapy in Breast Cancer

At the Crest of Innovation | Professors Jian Zhang and Songqing Ye Discuss the Frontiers of ADC Therapy in Breast Cancer

Antibody–drug conjugates (ADCs) are reshaping the treatment landscape of breast cancer at an unprecedented pace. From HER2 to Trop-2, and from late-line metastatic settings to early-stage neoadjuvant therapy, ADC indications continue to expand while efficacy breakthroughs accumulate. Oncology Frontier invited Professor Jian Zhang from Fudan University Shanghai Cancer Center and Professor Songqing Ye from Fujian Provincial Hospital to engage in an in-depth discussion on the evolution of ADCs, recent clinical advances, toxicity management, and future trends. Drawing on cutting-edge clinical data and real-world experience, the two experts offer valuable insights into efficacy optimization, toxicity management, frontline integration, combination strategies, and drug diversification.
The 8th Tongji Breast Cancer Forum | Professor Huihua Xiong: Integrating Top Academic Expertise to Advance Regional Breast Cancer Care

The 8th Tongji Breast Cancer Forum | Professor Huihua Xiong: Integrating Top Academic Expertise to Advance Regional Breast Cancer Care

With the arrival of spring, the 8th Tongji Breast Cancer Forum was successfully convened, focusing on key topics including clinical needs, cutting-edge advances, grassroots implementation, and the development of young physicians. The meeting not only built a bridge for in-depth dialogue between leading experts and frontline clinicians, but also offered fresh perspectives on integrating clinical practice with the latest scientific progress.
CSCO BC Preview | Professor Zefei Jiang: A Decade of Progress and a New Beginning—Join Us at the 2026 National Breast Cancer Conference

CSCO BC Preview | Professor Zefei Jiang: A Decade of Progress and a New Beginning—Join Us at the 2026 National Breast Cancer Conference

From April 10 to 12, 2026, the National Breast Cancer Conference will be held in Beijing. Marking the 10th anniversary of the Breast Cancer Committee of the Chinese Society of Clinical Oncology (CSCO BC), this annual flagship meeting will once again bring together leading experts from China and around the world to share cutting-edge research, interpret the latest guidelines and consensus statements, and exchange clinical experience—driving the high-quality development of breast cancer care in China. On the eve of the conference, Oncology Frontier invited Professor Zefei Jiang, Conference Chair and President-Elect of CSCO, to provide insights into the past decade of CSCO BC, the highlights of this year’s meeting, and key updates in the 2026 guidelines. We look forward to welcoming you in Beijing.
Beijing · April 24–25 | 2026 Beijing International Hematopoietic Stem Cell Transplantation Symposium (AOT 2026) to Convene

Beijing · April 24–25 | 2026 Beijing International Hematopoietic Stem Cell Transplantation Symposium (AOT 2026) to Convene

In order to comprehensively advance public health and strengthen strategies for the prevention and treatment of major diseases, medical innovation and international collaboration have become pivotal forces in overcoming critical health challenges. Against this backdrop, the 2026 Beijing International Hematopoietic Stem Cell Transplantation Symposium (Art of Transplant: Beijing Hematopoietic Stem Cell Transplantation Symposium, AOT 2026), hosted by the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care, and organized by the National Clinical Research Center for Hematologic Diseases and the Institute of Hematology at Peking University, will be grandly held in Beijing on April 24–25, 2026.
Voice of China at EBMT 2026 | Professor Erlie Jiang / Dr. Xiaoyu Zhang: Exploring the Role of Third-Generation TKIs in Transplantation for Blast-Phase CML

Voice of China at EBMT 2026 | Professor Erlie Jiang / Dr. Xiaoyu Zhang: Exploring the Role of Third-Generation TKIs in Transplantation for Blast-Phase CML

From March 22 to 25, 2026, the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain. As one of the most influential academic events in the field, the meeting brought together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy.
Professor Haixia Fu: Applications and Advances of TPO Receptor Agonists and ATRA in the Treatment of ITP

Professor Haixia Fu: Applications and Advances of TPO Receptor Agonists and ATRA in the Treatment of ITP

From March 27 to 28, 2026, the 9th Beijing Conference on Thrombosis and Hemostasis, hosted by the Hematologic Immunology Branch of the Chinese Society of Immunology, together with the 7th Beijing Summit Forum on Hematologic Malignancies and Immunology, was successfully held in Beijing. The meeting brought together leading international and domestic experts, clinicians, and industry leaders to explore cutting-edge developments in thrombosis and hemostasis, hematologic malignancies, and immunology, while advancing academic exchange and innovation in the field.